Oric Pharmaceuticals (ORIC) stock
ORIC's Quality Score fell 2 points on Tue, Oct 6, to -1. Its weekly trend stopped pointing up (2 chart checks stopped).
Follow ORIC's trial news. Pro members can get an alert when Oric Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
38.3% more shares than a year ago.
5 more reasons behind ORIC's -1, for Pro members
What's next for ORIC, and how long its cash lasts
From Oric Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Its trials
Cash runway
The company says its cash lasts into 2H 2028 (8-K, Aug 3).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Mar 11, 2024)
- At-the-market share sales program (424B5, filed Feb 23, 2026)
Insiders
Director Richard A. Heyman sold 6,700 shares on Oct 1, under a planned sale. 7 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why ORIC lags the market
Oric Pharmaceuticals returned -37% over five years to the S&P 500's +91%; its 4 peers' median returned -26%.
Its 4 peers' median return over five years was -26%, from -35% (Erasca) to +682% (Protagonist Therapeutics).
1 more driver, the timeline, and the peer table, for Pro members
Why ORIC scores -1
PoorTransition, 1 of 14 checks firingWhat the Quality Score means
- +2Long-term trend above a rising 200-day average
- −2Dilution 38.3% more shares outstanding than a year ago
- Chart checks adds
- Run-up adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Fri Oct 23: European Society of Medical…Industry event · date confirmed.
Expected to report Thu Nov 12, after the close
After its last 4 reports it closed +10.4% on average, higher 3 of 4 times.
What would turn ORIC's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ORIC has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1440.0
- MACD (12, 26, 9)Below signal
- 50-day average$12.97
- 200-day average$10.87
- ADX 1420.8
- Support$11.86
- Resistance$12.06
- Bollinger Bands (20, 2)Inside
- Volume1.3x
How ORIC ranks in Biotech
ORIC is #151 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
OLMAOpen for its score
ORKAOpen for its score
OSTXOpen for its score
ORIC1/14-1
When does ORIC report earnings, and what happens after?
Expected to report Thu Nov 12, after the close (in 37 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 3, 2026After close | After close | +0.4% | +27.1% | +28.5% |
| May 4, 2026After close | After close | -2.3% | -0.6% | -6.7% |
| Feb 23, 2026After close | After close | +3.2% | +14.6% | +18.5% |
| Nov 13, 2025After close | After close | +2.0% | +0.5% | -5.8% |
ORIC's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of ORIC's score, with the points and the reason
- All 14 checks on ORIC and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ORIC
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.